Risk-adapted Treatment Strategy For COVID-19 Patients
Background: There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19. Methods: We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity. Results: Twelve patients were in mild group and 22 were in moderate group (non-severe group, n = 34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p = 0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 nucleic acid negativity (p = 0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p = 0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis. Conclusions: Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 nucleic acid clearance and influence IgG antibody production..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:94 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 94(2020), Seite 74-77 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Changcheng Zheng [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antiviral treatment |
|---|
| doi: |
10.1016/j.ijid.2020.03.047 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ019712359 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ019712359 | ||
| 003 | DE-627 | ||
| 005 | 20230310112408.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.03.047 |2 doi | |
| 035 | |a (DE-627)DOAJ019712359 | ||
| 035 | |a (DE-599)DOAJaf70351be5e4465ea2ddb35b4594c622 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Changcheng Zheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk-adapted Treatment Strategy For COVID-19 Patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: There are no clear expert consensus or guidelines on how to treat 2019 coronavirus disease (COVID-19). The objective of this study is to investigate the short-term effect of risk-adapted treatment strategy on patients with COVID-19. Methods: We collected the medical records of 55 COVID-19 patients for analysis. We divided these patients into mild, moderate and severe groups, and risk-adapted treatment approaches were given according to the illness severity. Results: Twelve patients were in mild group and 22 were in moderate group (non-severe group, n = 34), and 21 patients were in severe group. At the end of the first two weeks after admission, clinical manifestations had completely despeared in 31(91.2%)patients in non-severe group, and 18(85.7%) patients in severe group (p = 0.85). Both groups had a satisfied chest CT imaging recovery, which includes 22(64.7%) patients in non-severe group and 12(57.1%) patients in severe group recovered at least 50% of the whole leisions in the first week, and 28(82.4%) and 16(76.2%) recovered at least 75% in the second week, respectively. There were no significant differences in SARS-CoV-2 nucleic acid negativity (p = 0.92). There were also no significant differences in the levels of SARS-CoV-2-IgM and IgG antibody production between the two groups (p = 0.13, 0.62). There were 45 cases were discharged from the hospital, and no patients died at the time of this clinical analysis. Conclusions: Risk-adapted treatment strategy was associated with significant clinical manifestations alleviation and clinical imaging recovery. In severe COVID-19 patients, early and short-term use of low-dose methylprednisolone was beneficial and did not delay SARS-CoV-2 nucleic acid clearance and influence IgG antibody production. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a novel coronavirus pneumonia | |
| 650 | 4 | |a risk-adapted treatment strategy | |
| 650 | 4 | |a antiviral treatment | |
| 650 | 4 | |a low-dose corticosteroid | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Jinquan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Hui Guo |e verfasserin |4 aut | |
| 700 | 0 | |a Zhaohui Lu |e verfasserin |4 aut | |
| 700 | 0 | |a Yan Ma |e verfasserin |4 aut | |
| 700 | 0 | |a Yuyou Zhu |e verfasserin |4 aut | |
| 700 | 0 | |a Daqing Xia |e verfasserin |4 aut | |
| 700 | 0 | |a Yinzhong Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Hongliang He |e verfasserin |4 aut | |
| 700 | 0 | |a Jian Zhou |e verfasserin |4 aut | |
| 700 | 0 | |a Yong Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Mingming Fei |e verfasserin |4 aut | |
| 700 | 0 | |a Yihong Yin |e verfasserin |4 aut | |
| 700 | 0 | |a Mao Zheng |e verfasserin |4 aut | |
| 700 | 0 | |a Yehong Xu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 94(2020), Seite 74-77 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:94 |g year:2020 |g pages:74-77 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2020.03.047 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/af70351be5e4465ea2ddb35b4594c622 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S120197122030179X |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 94 |j 2020 |h 74-77 | ||